Danuta is a CEO & Scientific Founder of Nucleome Therapeutics that spun out following a decade of research at Oxford University with the ambition to unlock the non-coding part of the genome for drug target discovery and development. Danuta has built Nucleome from inception into a leading biotech in functional genomics and led two successful investment rounds, including an oversubscribed Series A fundraise, bringing to date $55 million and a top-tier investor syndicate, including M Ventures, Johnson & Johnson Innovation JJDC Inc, Pfizer Ventures LLC, British Patient Capital, and founding investor Oxford Science Enterprises.
In acknowledgement of her achievements at Nucleome, Danuta was recognised as an outstanding leader in the biotech sector by leading scientific journal Nature Biotechnology. As a thought leader in genomics, Danuta is a Vice-Chair of the BioIndustry Association’s Genomics Advisory Committee, is a Member of the Date Health Subgroup for the Life Science Council and Member of the Functional Genomics Advisory Group for the Office of Life Sciences.
Prior to co-founding Nucleome, she founded Innovation Forum Oxford, for which she was recognised as one of the top Movers and Shakers in BioBusiness in 2018. Danuta has 18 years of experience in functional genomics and her scientific research at Oxford University, where she continues to hold an Honorary position, contributed into novel insights into how the dark genome functions in health and disease. Danuta is also an inventor of state-of-the-art 3D genome technique. She has a PhD in Systems Biology and a BSc in Biotechnology.
Your founding team can make a critical difference to the longterm success of your venture. “Who to hire, when and how are some of the most difficult questions for the founder of a life science venture. And where do I even begin to find the right people? Do I need a full time CSO and when? Do I need a CFO, or will a good accountant be a better fit in the early stages? When do I bring a CBO on board? Should all early hires get C-suite titles? What can I outsource, what must be kept internal?
These are just a few of the questions that we will discuss with Dr. Danuta Jeziorska this session who spun out Nucleome Therapeutics in 2019 and now has assembled seasoned leadership team and close to 50 employees.